Intensive chemotherapy for XXXX after primary @entity2590 .

@entity1 @entity981 @entity2590 @entity1503 @entity236 @entity3894
Twenty-five @entity1 with a primary @entity2590 ( @entity2590 ) transformed into @entity981 ( @entity981 ) were treated with intensive chemotherapy. A complete remission (CR) was obtained in six @entity1 (24 per cent). In five of these six @entity1 two courses of chemotherapy were needed to achieve CR. In eight @entity1 chemotherapy cleared the bone marrow of blasts, but the @entity3894 was fatal. A partial effect on @entity236 was seen in four @entity1 and no effect in another six. Eleven @entity1 (44 per cent) died from the consequences of chemotherapy-induced @entity1503 . A short interval between @entity2590 and transformation into @entity981 was associated with a better chance of achieving complete remission. Age, karyotype, type of @entity2590 , peripheral blood or bone marrow findings had no influence on the result of chemotherapy. The median survival from start of treatment was 5 months (range 0.5-24 months). In the @entity1 who achieved a CR, the median duration of the remission was 7 months (range 3-12 months). The poor response rate, the short duration of the remissions and the high treatment-related mortality suggest that current intensive anti-leukemic chemotherapy in @entity981 after primary @entity2590 is of limited benefit.
